

This article was originally published [here](#)

RUXIENCE is a monoclonal antibody (mAb) for the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA),

The post [Pfizer receives positive CHMP opinion for oncology biosimilar RUXIENCE](#) appeared first on [Pharmaceutical Business review](#).